These agents have a more favorable tolerance profile compared to that of chemotherapy for improving results and improve the results.4, 5, 6 Pembrolizumab was approved for advanced NSCLC first‐line with PD‐L1 Tumor Proportion Score (TPS) ≥50% based on the results of KEYNOTE‐024. This evidence concerns the gene CD274 and non-small cell lung carcinoma.